Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History

Nuvo Research Inc T.NRI

Sector: Healthcare | Sub-Sector: Drug Manufacturers - Specialty & Generic
Alternate Symbol(s):  NRIFF | NRIFD

Nuvo Research, Inc. is a Canadian specialty pharmaceutical company with manufacturing operations. The Company operates two distinct business units: the Topical Products and Technology (TPT) Group (formerly the Pain Group) and the Immunology Group.
Price: $2.61 | Change: $-0.09 | %Change: -3.33%
Volume: 5,625 | Day High/Low: 2.66/2.61 | 52 Week High/Low: 5.73/1.35


View modes: 
2.5 stars

RE:Generic Confusion

Generic  Confusion,,,,,,,,,,sorry but who was confused? THE TROUBLE WITH MARY,,,,,, I find it very difficult to believe that a person with so much pressumed knowledge about this biotech company...read more
5 stars

RE:Generic Confusion

Marianne, I'd rather you were involved in product related agreement negotiation than the car guys. I just don't think they have a deep enough understand of the market particulars to do a good job...read more
3.5 stars

RE:Generic Confusion

I for one am not jumping in any direction regarding possible partnerships with third party, I am pissed at the difference in being awarded a generic approval as per FDA and the company release that a...read more
5 stars

Generic Confusion

Ordinarily, the entry of low-cost competition isn't seen as a buy signal, but Nuvo's typically muddy news release is ambiguous enough that shareholders are willing to take it as good news.  Which it...read more
5 stars

RE:Pennsaid Generics Approvals - NRI 3rd party sales of Generic

Nuvo hopefully will earn a full wholesale margin on the generic.  rate and reply
3.5 stars

RE:RE:Buy Signal

WTF! Material? Maybe - maybe not. What's with management that they can't even issue a proper press release that tells shareholders what is going on. Thanks for finding the link  rate and reply
4 stars

Pennsaid Generics Approvals - NRI 3rd party sales of Generic

Igi Labs recieved "tentative" approval for topical Diclofenac Sodium on May 6.  Apotex recieved approval on May 27.  Since Apotex's approval is a full approval congruent with the message in the NRI...read more
3 stars

RE:Buy Signal

Nri to market through third party? Not mentioned in yesterdays release. http://fda.einnews.com/article_detail/207152222?lcode=8DWPqPuUsDVNDakfEIxsCA%3D%3D  rate and reply
3.5 stars

Buy Signal

The strong rebound in prices today set-off a bullish technical signal indicating a possible move back to the $4.00 level. We'll see what happens but for now $2.50 continues to hold support. ...read more
1 star

RE:Press Release

Terrible news for the Lil folk. Onwards and upwards..  rate and reply
5 stars

Press Release

Good news or bad - what are the implications for todays press release? Management really hasn't said much in the PR have they? Without sales or scripts written this is all pretty subjective news...read more
5 stars

RE:RE:RE:RE:RE:Nuvo Research NRI Insider Positions - WF10 Blockbuster Drug?

You are missing something. How much of Dan and John's salary is going towards stock units right now? We know when the stock was at $1.40 they were contributing 50%. We also knew that FDA approval...read more
3 stars

RE:RE:RE:RE:Nuvo Research NRI Insider Positions - WF10 Blockbuster Drug?

The positive side is, employees are not going to be involeved unless it is their better interest. In order for the employees to get involved is if the stock price increases. Unless I'm missing...read more
3.5 stars

RE:RE:RE:Nuvo Research NRI Insider Positions - WF10 Blockbuster Drug?

Deferred Share Unit Employee Plan (“DSU Employee Plan”) On June 18, 2013, the Corporation established the DSU Employee Plan, a share-based compensation plan for employees. Under this DSU Employee...read more
3 stars

Price manipulation

Incentives Clearly obvious here for PP , SARS and options. Bashers paid to keep price low as well as selling practises. IIROC might be interested .  rate and reply
3 stars

Time for Fast Action

Quick, the stock price is dropping... give management another raise! ;)  rate and reply
3 stars

RE:From the Cafe Pharma ...

Gosh, I don't know why it won't sell... we've been marketing slartybartfast like mad!  rate and reply
5 stars

MNK a Target?

Stymied by Meda, deal-hungry Mylan could jump on Stada or Mallinckrodt Read more: Stymied by Meda, deal-hungry Mylan could jump on Stada or Mallinckrodt - FiercePharma http://www.fiercepharma.com...read more
5 stars

From the Cafe Pharma ...

XartemisXR - Who was the genius that came up with this name? It's hard to say, hard to remember, hard to spell, and that's the Xartemis part. Then, they have to add the 'XR'. Why make it so hard on...read more
3 stars

RE:Do you ever get the feeling...

With global warming, there are supposed to be more icebergs as the icecaps melt. Be warned !!  rate and reply